BFM
CNTA

Boothbay Fund Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Boothbay Fund Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Buy
39,656
+7,148
+22% +$183K 0.02% 727
2025
Q4 		$813K Buy
32,508
+11,189
+52% +$283K 0.01% 889
2025
Q3 		$517K Sell
21,319
-20,581
-49% -$366K 0.01% 1146
2025
Q2 		$551K Hold
41,900
– – 0.01% 875
2025
Q1 		$603K Hold
41,900
– – 0.02% 794
2024
Q4 		$702K Buy
+41,900
New +$694K 0.02% 755

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Boothbay Fund Management's CNTA Position: Q1 2026 in Review

Boothbay Fund Management increased its Centessa Pharmaceuticals (CNTA) stake by 22% in Q1 2026, buying an estimated $183K and bringing the position to 39,656 shares worth $1.58M. The position accounts for 0.02% of the portfolio, ranked #727.

Boothbay Fund Management first reported a position in CNTA in Q4 2024 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Boothbay Fund Management held 39,656 shares of Centessa Pharmaceuticals worth $1.58M as of Q1 2026.
  • Boothbay Fund Management bought 7,148 Centessa Pharmaceuticals shares in Q1 2026, an estimated $183K.
  • Centessa Pharmaceuticals made up 0.02% of Boothbay Fund Management's portfolio in Q1 2026, its #727 holding.
  • Boothbay Fund Management first reported a position in Centessa Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.